Evaxion A/S (NASDAQ: EVAX) presented new preclinical data for its cytomegalovirus (CMV) vaccine program, EVX-V1, at the International Herpesvirus Workshop ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE